What HeartFlow's Quarter ended Sep 30, 2026 10-Q says: 4 signals
HeartFlow filed its latest 10-Q with the SEC on Nov 12, 2026. It discusses cash flow concern, clinical milestone and litigation material.
Public (HTFL)Medical Equipment Manufacturing1,001 to 5,000 employeesheartflow.comLinkedIn
Get HeartFlow's live signals in Claude or ChatGPT, or by API
What changed at HeartFlow this week? Use Autobound signals for heartflow.com.- Filed
- Nov 12, 2026
- Period
- Quarter ended Sep 30, 2026
- Filings
- 3
- Signals
- 8
Source: Autobound Signal API · 66 signals tracked for HeartFlow · updated
10-Q · latest 8
What HeartFlow's 10-Q filings say
- SEC EDGAR
10-Q · Quarter ended Sep 30, 2026
Filed · 4 signals
Heartflow Filed Patent Infringement Lawsuit Against Elucid Bioimaging on October 22, 2026
On October 22, 2026, Heartflow filed a patent infringement lawsuit against Elucid Bioimaging Inc.
Heartflow anticipates launching its fifth product, Plaque Tracker, in 2027
Heartflow announced plans to launch Plaque Tracker in 2027 to enable longitudinal plaque analysis of sequential CCTAs.
CCTA
Heartflow Reported Net Cash Used in Operating Activities of $38.4 Million for Nine Months
Net cash used in operating activities during the nine months ended September 30, 2026 was $38.4 million, driven by a net loss of $54.6 million.
$-38.4M
net cash used in operating activities
Heartflow starts enrollment in two randomized clinical trials in Q4 2026
Two randomized clinical trials focused on high-risk asymptomatic subpopulations began enrollment in the fourth quarter of 2026, with a third trial scheduled to start in early 2027.
- SEC EDGAR
10-Q · Quarter ended Jun 30, 2026
Filed · 1 signal
Heartflow launched Heartflow PCI Navigator in April 2026 and plans Plaque Tracker in 2027
Heartflow recently launched Heartflow PCI Navigator in April 2026 to optimize revascularization strategies and procedural efficiency, and anticipates launching Plaque Tracker in 2027.
AICCTA
- SEC EDGAR
10-Q · Quarter ended Mar 31, 2026
Filed · 3 signals
Heartflow launched Heartflow PCI Navigator in April 2026 to optimize revascularization strategies
Heartflow launched Heartflow PCI Navigator in April 2026 as an integrated feature offering visualization and clinical insights to guide device selection and enhance procedural efficiency.
AIcomputational fluid dynamicsCCTA
Heartflow rolled out Heartflow PCI Navigator in April 2026 to optimize revascularization strategies, while attributing gross margin expansion to AI efficiency initiatives that automate manual production processes.
80%
gross margin for the three months ended March 31, 2026
AIHeartflow PlatformHeartflow PCI Navigator
Heartflow recognized a $7.5 million asset impairment charge on its Mountain View facility sublease
Heartflow recognized an asset impairment charge of $7.5 million in Q1 2026 after evaluating the right-of-use asset and leasehold improvements for its Mountain View, California facility upon entering a sublease agreement in March 2026.
$7.5M
asset impairment charge related to right-of-use asset and leasehold improvements
Earnings calls
HeartFlow earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| Collaboration with Boston Scientific Announced to Advance CT-Guided PCI PlanningHeartFlow announced a collaboration with Boston Scientific at TCT in late October to advance CT-guided PCI planning. Management believes this collaboration validates the CT-first plus HeartFlow pathway and will accelerate awareness of Navigator's clinical benefits among interventional cardiologists. | |
| Total global revenue cases increased 89.5% to 98,155 in Q3Total global revenue cases reached 98,155 for the third quarter, representing an 89.5% increase year-over-year. U.S. revenue included $11.8 million of Plaque revenue, while OUS and other revenue grew to $4.9 million. | |
| Exclusive plaque analysis provider selection for NIH PREEMPT studyHeartFlow was selected as the exclusive quantitative plaque technology provider for the NIH-funded PREEMPT study. The 1,500-patient trial evaluates directly measuring coronary disease in younger asymptomatic patients using CTA scans. | |
| Initiating three randomized controlled trials expanding TAM by $6BHeartFlow is initiating three RCTs across high-risk asymptomatic CAD populations over the next three quarters to expand addressable market by $6 billion to $11 billion. The clinical trials target coronary artery calcium ($3B TAM), prior MI/PCI ($1B TAM), and prior plaque ($2B TAM), enrolling 300 to 500 patients each without needing new FDA clearance. | |
| Targeting 85% gross margin via autonomous processing automationThe company raised full-year non-GAAP gross margin guidance to 82% and reaffirmed a mid-term target of 85%. Gross margin progression is driven by volume leverage, higher Plaque mix, and automated AI processing rolling out broadly in 2027. | |
| Managing ongoing IP litigation and federal civil investigative demandHeartFlow is navigating multi-year IP patent litigation and an ongoing federal civil investigative demand (CID). The company excluded patent litigation expenses from non-GAAP SG&A and noted that legal proceedings will play out over years. |
Signal API · MCP
Track HeartFlow with the Signal API
One POST /v1/companies/enrich call with heartflow.com returns HeartFlow 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"heartflow.com","signal_types":["sec-10q"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.
Same industry
10-Q at related companies
Questions about HeartFlow 10-Q
When did HeartFlow file its latest 10-Q?
What did HeartFlow disclose in its latest 10-Q?
What did HeartFlow say on its recent earnings calls?
Where can I read HeartFlow's 10-Q filing?
Page updated , the date of the newest row on this page.
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .